主页 > 医学动态 >
【drug-news】Nuvelo 抗血栓新药临床效果不佳，Bay
Bayer, which paid $50 million when the deal was signed in January 2006, will pay Nuvelo (NASDAQ: NUVO - News) an additional $15 million within 30 days, Nuvelo said in a press release.
Bayer has the option to reacquire the right to develop and commercialize the drug outside the United States with an another $15 million payment.
The drug did not meet late-stage clinical trial markers for two trials treating blood clot disorders, the companies said in December, and a third study was put on hold.
But Nuvelo officials said the company will begin a phase 2 proof-of-concept trial with alfimeprase in the second half. Plus, a phase 3 trial, using a higher dosage, also will begin in the second half.
"We believe that a safer, more efficacious intra-arterial therapy can change the treatment paradigm for these patients and that a product candidate such as alfimeprase holds the potential to rapidly restore flow and expand the treatment window beyond the current three-hour timeframe," said Nuvelo Chairman and CEO Ted Love. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-25 05:11
医学,生命科学网